CARA [NASD]
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own0.60% Shs Outstand53.73M Perf Week12.22%
Market Cap628.62M Forward P/E- EPS next Y-0.37 Insider Trans-10.67% Shs Float45.04M Perf Month35.91%
Income-88.50M PEG- EPS next Q-0.32 Inst Own66.80% Short Float / Ratio13.68% / 17.93 Perf Quarter20.33%
Sales39.40M P/S15.95 EPS this Y23.00% Inst Trans-0.36% Short Interest6.16M Perf Half Y48.34%
Book/sh3.44 P/B3.63 EPS next Y72.40% ROA-38.90% Target Price23.62 Perf Year1.46%
Cash/sh3.09 P/C4.04 EPS next 5Y- ROE-43.10% 52W Range7.40 - 13.97 Perf YTD2.55%
Dividend- P/FCF- EPS past 5Y3.60% ROI-39.20% 52W High-12.71% Beta0.98
Dividend %- Quick Ratio6.60 Sales past 5Y205.90% Gross Margin87.00% 52W Low64.73% ATR0.55
Employees84 Current Ratio6.60 Sales Q/Q-46.80% Oper. Margin- RSI (14)65.98 Volatility5.35% 5.23%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.34 Prev Close12.49
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume343.61K Price12.19
Recom1.70 SMA2010.35% SMA5020.20% SMA20019.29% Volume54,444 Change-2.40%
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Show Previous Ratings
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
04:01PM
Nov-04-22 08:46AM
07:00AM Loading…
Nov-03-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
07:00AM Loading…
Sep-12-22 07:00AM
Sep-08-22 02:27PM
08:15AM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
04:01PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
Jul-22-22 06:39AM
Jun-30-22 10:19AM
07:00AM Loading…
07:00AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
May-09-22 05:25PM
04:01PM
May-04-22 09:05AM
May-03-22 04:01PM
Apr-29-22 07:00AM
Apr-28-22 01:00AM
Apr-13-22 11:17AM
07:46AM
Apr-05-22 07:00AM
Apr-04-22 04:01PM
Mar-28-22 12:13PM
07:00AM
Mar-08-22 04:01PM
Mar-01-22 05:15PM
04:01PM
09:35AM
Feb-25-22 07:15AM
Feb-22-22 04:01PM
Feb-18-22 07:00AM
Feb-17-22 03:03PM
Feb-15-22 11:19AM
Feb-14-22 10:29AM
Feb-12-22 06:45AM
Feb-10-22 05:35PM
Feb-08-22 08:05AM
Feb-04-22 08:05AM
Jan-28-22 12:48PM
12:44PM
Jan-25-22 12:45PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
Dec-20-21 07:00AM
Dec-14-21 05:10AM
Nov-18-21 08:30AM
Nov-17-21 12:01PM
Nov-09-21 04:30PM
Nov-08-21 08:30PM
05:15PM
04:01PM
Nov-03-21 08:00AM
06:22AM
Nov-01-21 04:15PM
03:01PM
Oct-26-21 10:18AM
Oct-15-21 06:59AM
Oct-04-21 07:00AM
Sep-29-21 07:00AM
Sep-24-21 07:00AM
07:00AM
Sep-20-21 04:26PM
Sep-04-21 08:55AM
Aug-27-21 05:33PM
Aug-24-21 04:08PM
02:13PM
11:06AM
10:57AM
07:40AM
06:02AM
01:00AM
Aug-23-21 07:06PM
03:55PM
03:41PM
Aug-15-21 08:07AM
Aug-11-21 10:22AM
Aug-09-21 09:00PM
05:25PM
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner ChristopherPresident and CEONov 16Sale11.1314,470161,051186,561Nov 18 05:23 PM
VOGELBAUM MARTINDirectorSep 14Sale10.2810,800111,02444,988Sep 16 04:21 PM
Ives Jeffrey L.DirectorJul 15Sale9.053,60032,58015,476Jul 19 05:16 PM
BAINS HARRISON M JRDirectorJul 15Sale9.057,20065,16025,076Jul 19 05:13 PM
Posner ChristopherPresident and CEOApr 04Sale12.672,00625,416201,031Apr 05 05:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 01Sale11.911,64219,556102,344Apr 05 05:51 PM
Goncalves JoanaChief Medical OfficerApr 01Sale11.911,64219,55674,893Apr 05 05:50 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 01Sale11.911,78421,247169,781Apr 05 05:49 PM
Reilly Thomas CharlesChief Financial OfficerMar 03Sale11.382,04423,26137,811Mar 04 05:54 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 03Sale11.381,78720,336103,986Mar 04 05:51 PM
Goncalves JoanaChief Medical OfficerFeb 25Sale10.291,97220,29276,535Mar 01 04:14 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Feb 25Sale10.291,97220,292100,440Mar 01 04:19 PM